Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
종목 코드 BJDX
회사 이름Bluejay Diagnostics Inc
상장일Nov 10, 2021
CEODey (Neil)
직원 수7
유형Ordinary Share
회계 연도 종료Nov 10
주소360 Massachusetts Avenue, Suite 203
도시ACTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호01720
전화19786310152
웹사이트https://bluejaydx.com/
종목 코드 BJDX
상장일Nov 10, 2021
CEODey (Neil)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음